Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.

Suppr

超能文献

作者信息

Farese R V, Schambelan M, Hollander H, Stringari S, Jacobson M A

机构信息

San Francisco General Hospital, California.

出版信息

Ann Intern Med. 1990 Jun 15;112(12):955-6. doi: 10.7326/0003-4819-112-12-955.

DOI:10.7326/0003-4819-112-12-955

PMID:2160217

Abstract

摘要

相似文献

Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.

Ann Intern Med. 1990 Jun 15;112(12):955-6. doi: 10.7326/0003-4819-112-12-955.

Foscarnet.

Med Lett Drugs Ther. 1992 Jan 10;34(861):3-4.

Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.

Lancet. 1991 Jul 27;338(8761):250. doi: 10.1016/0140-6736(91)90385-3.

Seeing the way forward for treatment of CMV retinitis.

Lancet. 1991 Dec 14;338(8781):1494-5.

Treatment of CMV retinitis.

Lancet. 1992 Jan 25;339(8787):247. doi: 10.1016/0140-6736(92)90049-9.

Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.膦甲酸钠治疗获得性免疫缺陷综合征相关巨细胞病毒性视网膜炎患者的随机对照试验设计

Am J Med. 1992 Feb 14;92(2A):22S-25S. doi: 10.1016/0002-9343(92)90333-7.

Treatment of cytomegalovirus retinitis--1992.巨细胞病毒性视网膜炎的治疗——1992年。

Arch Ophthalmol. 1992 Feb;110(2):185-7. doi: 10.1001/archopht.1992.01080140041022.

Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.获得性免疫缺陷综合征患者巨细胞病毒性视网膜炎的维持治疗：膦甲酸钠。

Am J Med. 1992 Feb 14;92(2A):26S-29S. doi: 10.1016/0002-9343(92)90334-8.

Treatment of CMV retinitis.

N Engl J Med. 1992 Jun 18;326(25):1702.

A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.一项关于膦甲酸钠治疗艾滋病患者巨细胞病毒性视网膜炎的随机对照试验。

Ann Intern Med. 1991 Nov 1;115(9):665-73. doi: 10.7326/0003-4819-115-9-665.

引用本文的文献

Drug-induced diabetes insipidus: incidence, prevention and management.药物性尿崩症：发病率、预防与管理

Drug Saf. 1999 Dec;21(6):449-56. doi: 10.2165/00002018-199921060-00002.

Comparative tolerability of therapies for cytomegalovirus retinitis.巨细胞病毒性视网膜炎治疗方法的耐受性比较

Drug Saf. 1999 Sep;21(3):203-24. doi: 10.2165/00002018-199921030-00005.

Minimising the dosage-limiting toxicities of foscarnet induction therapy.尽量减少膦甲酸诱导疗法的剂量限制性毒性。

Drug Saf. 1997 Apr;16(4):258-66. doi: 10.2165/00002018-199716040-00003.

Foscarnet alters antidiuretic hormone-mediated transport.膦甲酸钠改变抗利尿激素介导的转运。

Antimicrob Agents Chemother. 1995 Sep;39(9):2008-12. doi: 10.1128/AAC.39.9.2008.

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.膦甲酸钠。对其在免疫功能低下的病毒感染患者中的抗病毒活性、药代动力学特性及治疗用途的重新评估。

Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007.

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.膦甲酸钠。对其在免疫功能低下的巨细胞病毒性视网膜炎患者中的抗病毒活性、药代动力学特性及治疗应用的综述。

Drugs. 1991 Jan;41(1):104-29. doi: 10.2165/00003495-199141010-00009.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验